市場調査レポート

商品コード

1700049

血漿分画製剤市場の2032年までの予測：タイプ別、プロセス別、用途別、エンドユーザー別、地域別の世界分析

Blood Plasma Derivatives Market Forecasts to 2032 - Global Analysis By Type, Process, Application, End User and By Geography

出版日: 2025年04月03日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 600,256円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 759,360円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 918,464円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,084,800円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.64円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の血漿分画製剤市場は2025年に567億1,000万米ドルを占め、2032年には1,155億2,000万米ドルに達すると予測され、予測期間中のCAGRは10.7％です。

血液の液体成分であるヒト血漿は、血漿分画製剤として知られる特殊な医薬品の原料です。アルブミン、免疫グロブリン、凝固因子、α-1抗トリプシンのような必須タンパク質はこれらの誘導体の一つであり、様々な病気の治療に頻繁に使用されています。免疫不全症、血友病、ギラン・バレー症候群のような神経症状は、すべてこれらの助けを借りて治療されています。医療用に特定のタンパク質を分離・精製するために使用される技術である分画によって、血漿分画製剤が得られます。

世界血友病連盟（WFH）によると、血友病は世界で約1万人に1人の割合で発症しています。

高齢者の増加

血漿由来療法の需要増加の主な要因は、人口の高齢化です。高齢者は凝固障害、慢性肝疾患、免疫不全などの病気にかかりやすいため、血漿分画製剤の重要なユーザーです。国連の推計によれば、2050年までに約16億人、つまり世界の6人に1人が65歳以上になるといいます。さらに、感染症、心血管疾患、自己免疫疾患のリスクは加齢とともに増加します。これらの疾患の多くは、アルブミンや免疫グロブリンなどの血漿タンパク質で治療されます。

製造と加工にかかる法外な費用

複雑で時間のかかる血漿分画プロセスにより、血漿由来の治療薬の製造は非常にコストがかかります。血漿の採取から最終製品のリリースまで7～12ヵ月かかることもあり、その結果、運営コストが高くなります。血漿タンパク質の安定性と有効性を維持するためには、血漿分画には特殊な機器、厳格な品質管理試験、大規模な保管インフラが必要となります。さらに、少量の完成品を作るのに数リットルの血漿が必要なため、総製造コストが上昇します。例えば、1人の患者を1年間治療するのに十分な量の静脈内免疫グロブリン（IVIG）を作るには、約130の血漿提供が必要です。

免疫グロブリンと血漿治療への関心の高まり

免疫不全、神経疾患、自己免疫疾患の増加により、免疫グロブリン静注療法（IVIG）や免疫グロブリン皮下注療法（SCIG）の需要が高まっています。川崎病、慢性炎症性脱髄性多発ニューロパチー（CIDP）、原発性免疫不全症（PIDD）などの疾患では、長期の免疫グロブリン療法が必要です。業界の推計によると、IVIGの需要は世界的に年率8％以上で増加しており、市場には大きな成長の見通しが生まれています。さらに、血漿由来免疫グロブリン治療の適応症が敗血症、多発性硬化症、アルツハイマー病などの疾患にも拡大されたことで、市場の見通しはさらに高まっています。

血漿提供の不足と供給の制限

血漿の世界の供給はドナーの参加に大きく依存しており、その参加は社会経済的要因、規制の制限、血漿提供に関する一般市民の態度によって異なります。政策変更やドナー補償の倫理的議論は、米国のような補償付き血漿提供モデルに依存している国に混乱を引き起こす可能性があります。さらに、COVID-19のパンデミックは、顕著な献血の減少が免疫グロブリンと凝固因子の不足をもたらしたことから、血漿収集の脆弱性を明るみに出しました。

COVID-19の影響：

COVID-19パンデミックは、製造の遅れ、血漿採取の中断、免疫グロブリンの需要増を引き起こしたため、血漿分画製剤の市場に大きな影響を与えました。特に米国や欧州のような重要な市場では、ロックダウンや社会的距離を置く政策によって血漿提供が減少し、血漿由来の重要な治療薬が不足する結果となりました。さらに、他の血漿由来製品のサプライチェーンも、COVID-19患者のための回復期血漿療法に関する研究の爆発的な増加によって引き起こされた業界の一時的な焦点のシフトによって影響を受けた。

予測期間中、免疫グロブリンセグメントが最大となる見込み

自己免疫疾患、原発性および二次性免疫不全症、ギラン・バレー症候群や慢性炎症性脱髄性多発神経炎（CIDP）などの神経疾患の治療に幅広く応用されていることから、予測期間中、免疫グロブリン分野が最大の市場シェアを占めると予想されます。免疫グロブリン製剤の需要は、高齢者の増加、免疫不全症の有病率の増加、血漿由来の治療法に関する知識の増加によって牽引されています。さらに、静脈内投与（IVIG）および皮下投与（SCIG）用の免疫グロブリン製剤の改良により、患者の利便性と治療コンプライアンスが向上しています。

予測期間中、クロマトグラフィー分野のCAGRが最も高くなる見込み

予測期間中、血漿タンパク質の分離における卓越した効率性、純度、精度を背景に、クロマトグラフィー部門が最も高い成長率を示すと予測されます。クロマトグラフィーは免疫グロブリン、アルブミン、凝固因子の製造にますます普及しているが、その理由はコールドエタノール分画のような従来の技術に比べて優れた収率と特異性が得られるからです。高純度血漿由来の治療に対する需要の高まり、アフィニティークロマトグラフィーやイオン交換クロマトグラフィーの改良、バイオ医薬品研究への投資の増加などが、クロマトグラフィーの急速な普及に拍車をかけています。さらに、クロマトグラフィーを用いた精製は、その優れた病原体除去能力から規制当局が好んで使用することで、市場の成長がさらに加速しています。

最大のシェアを占める地域

予測期間中、北米地域が最大の市場シェアを占めると予想されます。これは、大手市場プレイヤーの強固なプレゼンス、高い血漿提供率、洗練されたヘルスケアインフラが背景にあります。確立された血漿提供施設と有利な償還政策により、米国はこの地域をリードし、世界の血漿収集に大きく貢献しています。同市場は、神経疾患、血友病、免疫疾患の罹患率の上昇や、血漿由来の治療法に対する意識の高まりによって成長しています。さらに、北米が市場を独占しているのは、FDAによる強力な規制支援、血漿分画技術に関する継続的な調査、免疫グロブリン治療の普及の結果でもあります。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域が最も高いCAGRを示すと予測されます。これは、免疫不全疾患の有病率の増加、血漿由来治療に対する意識の高まり、ヘルスケアコストの上昇による。生物製剤や血漿分画に対する政府の支援、血漿採取プログラムの増加、医療インフラの充実などが、中国、インド、日本などの急速な拡大に寄与しています。凝固因子や免疫グロブリンに対する需要の高まりに加え、高度な精製技術への投資や医薬品製造能力の拡大により、市場は拡大しています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、ジョイントベンチャー
買収と合併
新製品発売
事業拡大
その他の主要戦略

第11章企業プロファイリング

Bayer AG
Fusion Health Care Pvt. Ltd.
Grifols, S.A.
Takeda Pharmaceutical Company
Sanofi
CSL Limited
LFB S.A.
Baxter International Inc.
Syntegon
Green Cross Corporation
Octapharma AG
Biotest AG
Kedrion Biopharma, Inc.
SK Plasma Co., Ltd.
Intas Pharmaceuticals Ltd.

図表

List of Tables

Table 1 Global Blood Plasma Derivatives Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
Table 3 Global Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
Table 4 Global Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
Table 5 Global Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
Table 6 Global Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
Table 7 Global Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
Table 8 Global Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
Table 9 Global Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
Table 10 Global Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
Table 11 Global Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
Table 12 Global Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
Table 13 Global Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
Table 14 Global Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
Table 15 Global Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
Table 16 Global Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
Table 17 Global Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
Table 18 Global Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
Table 19 Global Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
Table 20 Global Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
Table 21 Global Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
Table 22 Global Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
Table 23 North America Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
Table 24 North America Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
Table 25 North America Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
Table 26 North America Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
Table 27 North America Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
Table 28 North America Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
Table 29 North America Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
Table 30 North America Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
Table 31 North America Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
Table 32 North America Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
Table 33 North America Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
Table 34 North America Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
Table 35 North America Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
Table 36 North America Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
Table 37 North America Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
Table 38 North America Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
Table 39 North America Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
Table 40 North America Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
Table 41 North America Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
Table 42 North America Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
Table 43 North America Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
Table 44 North America Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
Table 45 Europe Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
Table 46 Europe Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
Table 47 Europe Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
Table 48 Europe Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
Table 49 Europe Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
Table 50 Europe Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
Table 51 Europe Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
Table 52 Europe Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
Table 53 Europe Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
Table 54 Europe Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
Table 55 Europe Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
Table 56 Europe Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
Table 57 Europe Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
Table 58 Europe Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
Table 59 Europe Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
Table 60 Europe Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
Table 61 Europe Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
Table 62 Europe Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
Table 63 Europe Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
Table 64 Europe Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
Table 65 Europe Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
Table 66 Europe Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
Table 67 Asia Pacific Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
Table 68 Asia Pacific Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
Table 69 Asia Pacific Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
Table 70 Asia Pacific Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
Table 71 Asia Pacific Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
Table 72 Asia Pacific Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
Table 73 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
Table 74 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
Table 75 Asia Pacific Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
Table 76 Asia Pacific Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
Table 77 Asia Pacific Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
Table 78 Asia Pacific Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
Table 79 Asia Pacific Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
Table 80 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
Table 81 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
Table 82 Asia Pacific Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
Table 83 Asia Pacific Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
Table 84 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
Table 85 Asia Pacific Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
Table 86 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
Table 87 Asia Pacific Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
Table 88 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
Table 89 South America Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
Table 90 South America Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
Table 91 South America Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
Table 92 South America Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
Table 93 South America Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
Table 94 South America Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
Table 95 South America Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
Table 96 South America Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
Table 97 South America Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
Table 98 South America Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
Table 99 South America Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
Table 100 South America Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
Table 101 South America Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
Table 102 South America Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
Table 103 South America Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
Table 104 South America Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
Table 105 South America Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
Table 106 South America Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
Table 107 South America Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
Table 108 South America Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
Table 109 South America Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
Table 110 South America Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)
Table 111 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Country (2024-2032) ($MN)
Table 112 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Type (2024-2032) ($MN)
Table 113 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) ($MN)
Table 114 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) ($MN)
Table 115 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) ($MN)
Table 116 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) ($MN)
Table 117 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) ($MN)
Table 118 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) ($MN)
Table 119 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Process (2024-2032) ($MN)
Table 120 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) ($MN)
Table 121 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) ($MN)
Table 122 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) ($MN)
Table 123 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Application (2024-2032) ($MN)
Table 124 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) ($MN)
Table 125 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) ($MN)
Table 126 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) ($MN)
Table 127 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) ($MN)
Table 128 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) ($MN)
Table 129 Middle East & Africa Blood Plasma Derivatives Market Outlook, By End User (2024-2032) ($MN)
Table 130 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) ($MN)
Table 131 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) ($MN)
Table 132 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) ($MN)

Product Code: SMRC28952

According to Stratistics MRC, the Global Blood Plasma Derivatives Market is accounted for $56.71 billion in 2025 and is expected to reach $115.52 billion by 2032 growing at a CAGR of 10.7% during the forecast period. Human plasma, the liquid component of blood, is the source of specialized medicinal products known as blood plasma derivatives. Essential proteins like albumin, immunoglobulins, clotting factors, and alpha-1 antitrypsin are among these derivatives and are frequently used to treat a variety of illnesses. Immunodeficiencies, hemophilia, and neurological conditions like Guillain-Barre syndrome are all treated with their help. Fractionation, a technique used to isolate and purify particular proteins for medical applications, yields plasma derivatives.

According to the World Federation of Hemophilia (WFH), hemophilia affects approximately 1 in 10,000 people globally.

Market Dynamics:

Driver:

Increasing number of elderly people

A major factor in the rising demand for therapies derived from plasma is the aging population. The elderly are significant users of plasma derivatives because they are more susceptible to diseases like coagulation problems, chronic liver disease, and immunological deficiencies. Approximately 1.6 billion people, or one in six people worldwide, will be over 65 by 2050, according to UN estimates. Additionally, the risk of infections, cardiovascular conditions, and autoimmune diseases increases with age; many of these conditions are treated with plasma proteins such as albumin and immunoglobulins.

Restraint:

Exorbitant expenses for production and processing

The complicated and time-consuming plasma fractionation process makes the production of therapies derived from plasma extremely costly. Plasma collection and final product release can take seven to twelve months, which results in high operating costs. For plasma proteins to remain stable and effective, plasma fractionation necessitates specialized equipment, rigorous quality control testing, and a sizable storage infrastructure. Furthermore, the total cost of production is raised by the requirement for several liters of plasma to generate a small amount of the finished product. For instance, to make enough Intravenous Immunoglobulin (IVIG) to treat one patient for a year, about 130 plasma donations are needed.

Opportunity:

Growing interest in immunoglobulin and plasma treatments

Intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) are in high demand due to the increasing incidence of immune deficiencies, neurological conditions, and autoimmune diseases. Long-term immunoglobulin therapy is necessary for conditions like Kawasaki disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and primary immunodeficiency disorders (PIDD). Industry estimates indicate that the demand for IVIG has been rising globally at a rate of more than 8% per year, which has created significant growth prospects for the market. Moreover, prospects for the market are further enhanced by the extension of plasma-derived immunoglobulin treatment indications into conditions like sepsis, multiple sclerosis, and Alzheimer's disease.

Threat:

Lack of plasma donations and limitations on supply

The worldwide supply of plasma is largely reliant on donor participation, which varies depending on socioeconomic factors, regulatory limitations, and public attitudes regarding plasma donation. Policy changes and donor compensation ethical discussions could cause disruptions for nations like the US that depend on compensated plasma donation models. Additionally, the COVID-19 pandemic brought to light the vulnerability of plasma collection, as notable drops in donations resulted in immunoglobulin and clotting factor shortages.

Covid-19 Impact:

The COVID-19 pandemic had a major effect on the market for blood plasma derivatives because it caused delays in manufacturing, disruptions in plasma collection, and an increase in demand for immunoglobulins. Lockdowns and social distancing policies caused plasma donations to drop, particularly in important markets like the US and Europe, which resulted in a shortage of vital therapies derived from plasma. Furthermore, the supply chain for other plasma-derived products was also impacted by the brief shift in industry focus caused by the explosion in research on convalescent plasma therapy for COVID-19 patients.

The Immunoglobulin segment is expected to be the largest during the forecast period

The Immunoglobulin segment is expected to account for the largest market share during the forecast period, motivated by its extensive application in the treatment of autoimmune diseases, primary and secondary immunodeficiency's, and neurological disorders like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP). The demand for immunoglobulin products has been driven by the growing number of elderly people, the increasing prevalence of immunodeficiency diseases, and the growing knowledge of plasma-derived treatments. Furthermore, improvements in immunoglobulin formulations for intravenous (IVIG) and subcutaneous (SCIG) administration have enhanced patient convenience and treatment compliance.

The Chromatography segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Chromatography segment is predicted to witness the highest growth rate, motivated by its exceptional efficiency, purity, and precision in plasma protein separation. Chromatography is becoming more and more popular for producing immunoglobulins, albumin, and coagulation factors because it provides superior yield and specificity compared to conventional techniques like cold ethanol fractionation. Its quick adoption is being fueled by the rising demand for high-purity plasma-derived treatments, improvements in affinity and ion-exchange chromatography, and rising investments in biopharmaceutical research. Moreover, the market growth of chromatography-based purification is further enhanced by regulatory bodies' preference for it because of its superior pathogen removal capabilities.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by a robust presence of major market players, high plasma donation rates, and sophisticated healthcare infrastructure. Because of its well-established plasma donation facilities and advantageous reimbursement policies, the United States leads the region and contributes significantly to global plasma collection. The market is growing due to the rising incidence of neurological diseases, hemophilia, and immune disorders, as well as increased awareness of therapies derived from plasma. Additionally, North America's dominant market position is also a result of the FDA's strong regulatory support, continuous research into plasma fractionation technologies, and widespread use of immunoglobulin treatments.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by the growing prevalence of immunodeficiency disorders, growing awareness of plasma-derived therapies, and rising healthcare costs. Government support for biologics and plasma fractionation, growing plasma collection programs, and better healthcare infrastructure are all contributing to the rapid expansion of nations like China, India, and Japan. The market is growing as a result of rising demand for coagulation factors and immunoglobulins, as well as investments in sophisticated purification technologies and growing pharmaceutical manufacturing capacities.

Key players in the market

Some of the key players in Blood Plasma Derivatives Market include Bayer AG, Fusion Health Care Pvt. Ltd., Grifols, S.A., Takeda Pharmaceutical Company, Sanofi, CSL Limited, LFB S.A., Baxter International Inc., Syntegon, Green Cross Corporation, Octapharma AG, Biotest AG, Kedrion Biopharma, Inc., SK Plasma Co., Ltd. and Intas Pharmaceuticals Ltd.

Key Developments:

In February 2025, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). The terms of the transaction remain unchanged from those previously announced and closing is expected in the second quarter of 2025 at the earliest.

In January 2025, Bayer announced that the company has signed a new exclusive distribution agreement with UK-based Ecospray to market a biological liquid nematicide sourced from garlic. The product presents a biological alternative to traditional synthetic chemical nematicides in vegetable and potato crops, and will be marketed in the European Union under the new name Velsinum(TM).

In June 2024, Takeda announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.

Types Covered:

Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Other Types

Processes Covered:

Cold Ethanol Fractionation
Heat Treatment
Chromatography

Applications Covered:

Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
Von Willebrand'S Disease
Other Applications

End Users Covered:

Hospitals
Clinics
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Blood Plasma Derivatives Market, By Type

5.1 Introduction
5.2 Albumin
5.3 Factor VIII
5.4 Factor IX
5.5 Immunoglobulin
5.6 Hyperimmune Globulin
5.7 Other Types

6 Global Blood Plasma Derivatives Market, By Process

6.1 Introduction
6.2 Cold Ethanol Fractionation
6.3 Heat Treatment
6.4 Chromatography

7 Global Blood Plasma Derivatives Market, By Application

7.1 Introduction
7.2 Hemophilia
7.3 Hypogammaglobulinemia
7.4 Immunodeficiency Diseases
7.5 Von Willebrand'S Disease
7.6 Other Applications

8 Global Blood Plasma Derivatives Market, By End User

8.1 Introduction
8.2 Hospitals
8.3 Clinics
8.4 Other End Users

9 Global Blood Plasma Derivatives Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Bayer AG
11.2 Fusion Health Care Pvt. Ltd.
11.3 Grifols, S.A.
11.4 Takeda Pharmaceutical Company
11.5 Sanofi
11.6 CSL Limited
11.7 LFB S.A.
11.8 Baxter International Inc.
11.9 Syntegon
11.10 Green Cross Corporation
11.11 Octapharma AG
11.12 Biotest AG
11.13 Kedrion Biopharma, Inc.
11.14 SK Plasma Co., Ltd.
11.15 Intas Pharmaceuticals Ltd.

血漿分画製剤市場の2032年までの予測： タイプ別、プロセス別、用途別、エンドユーザー別、地域別の世界分析

Blood Plasma Derivatives Market Forecasts to 2032 - Global Analysis By Type, Process, Application, End User and By Geography

COVID-19の影響：

最大のシェアを占める地域

CAGRが最も高い地域：

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の血漿分画製剤市場：タイプ別

第6章 世界の血漿分画製剤市場：プロセス別

第7章 世界の血漿分画製剤市場：用途別

第8章 世界の血漿分画製剤市場：エンドユーザー別

第9章 世界の血漿分画製剤市場：地域別

第10章 主な発展

第11章 企業プロファイリング